Tmax evidence

Peptide

ATLPC0027686

Measured material

Specific molecular form

Endpoint

Tmax

ADMET domain

Exposure / Absorption

Value

Observation

route=deep subcutaneous; population=acromegalic patients; state=repeat dose; statistic=time window for peak levels; source_value=during the first day after administration

Evidence role

Reported: reviewed reported observation that should not be pooled as a comparable value yet

Assay / model

human

Condition

Lanreotide · 6e4a41fd-a753-4362-87ee-8cc56ed3660d · 12.3 Pharmacokinetics · lanreotide repeat dose tmax within first day · Acromegaly In a repeat-dose administration pharmacokinet...

Scientific source

DailyMed

Open source

Tmax evidence

Developability

Resources

Measurement